These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38669613)
1. Non-Small Cell Lung Cancer Metastatic Without Oncogenic Alterations. Frost N; Reck M Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432524. PubMed ID: 38669613 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M Front Immunol; 2021; 12():799455. PubMed ID: 35069581 [TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Dafni U; Tsourti Z; Vervita K; Peters S Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971 [TBL] [Abstract][Full Text] [Related]
4. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653 [TBL] [Abstract][Full Text] [Related]
6. Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Liu J; Chen M; Gao X; Liu X; Zhao J; Pan R; Zhong W; Xu Y; Wang M Thorac Cancer; 2023 Mar; 14(8):773-778. PubMed ID: 36725772 [TBL] [Abstract][Full Text] [Related]
7. A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S Clin Lung Cancer; 2022 Nov; 23(7):e400-e404. PubMed ID: 35863963 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis. Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. Saxena P; Singh PK; Malik PS; Singh N Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019 [TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome. Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T Front Immunol; 2021; 12():651086. PubMed ID: 34248939 [TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer. Yu H; Chen P; Xia L; Fu S; Chen C; Zhang X; He L; Zhang B; Zhou Y; Hong S J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34750245 [TBL] [Abstract][Full Text] [Related]
12. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Zhou F; Qiao M; Zhou C Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696 [TBL] [Abstract][Full Text] [Related]
13. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. Passaro A; Brahmer J; Antonia S; Mok T; Peters S J Clin Oncol; 2022 Feb; 40(6):598-610. PubMed ID: 34985992 [TBL] [Abstract][Full Text] [Related]
14. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Zouein J; Haddad FG; Eid R; Kourie HR Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502 [TBL] [Abstract][Full Text] [Related]
15. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy. Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J Front Immunol; 2023; 14():1089026. PubMed ID: 36776868 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study. Roh J; Eom JS; Lee MK; Kim J; Jang T; Yoon SH; Son CH; Lee HK; Kim HK; Lee SY; Shin KC; Kim MH Am J Clin Oncol; 2021 Jul; 44(7):356-360. PubMed ID: 34014843 [TBL] [Abstract][Full Text] [Related]
17. Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. Qin A; Lima F; Bell S; Kalemkerian GP; Schneider BJ; Ramnath N; Lew M; Krishnan S; Mohammed S; Rao A; Frankel TL Sci Rep; 2022 May; 12(1):9054. PubMed ID: 35641540 [TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062 [TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). Xu Z; Li T; Hu X; Hao X; Xing P; Li J Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]